CURRICULUM VITAE

DR. HERWIG P. MOLL
Nationality: Austria
Medical University of Vienna
Center for Physiology and Pharmacology
Waehringer Str. 13a, 1090 Vienna, Austria
Email: herwig.moll@meduniwien.ac.at
phone: (+43) 1 40160 31344
Orcid: 0000-0001-6438-9068
Web: www.meduniwien.ac.at/hp/en/zpp/

1. POSTGRADUATE PROFESSIONAL CAREER

11/2014 – to date Assistant
Medical University of Vienna
Center for Physiology and Pharmacology

04/2011 – 09/2014 Postdoctoral Research Fellow
Beth Israel Deaconess Medical Center and Harvard Medical School
Department of Surgery,
Boston, Massachusetts, United States
Principal Investigator: Christiane Ferran, MD, PhD

10/2010 – 02/2011 Research Associate
Jungbunzlauer AG Austria,
Department of Product Development
Pernhofen, Austria

2. UNIVERSITY TRAINING

09/2007 – 05/2010 PhD-student
Medical University of Vienna, Austria
Department of Surgery
PhD Thesis: *"Induction of Interferon Regulated Genes in Endothelial Cells: Differential Regulation by Interferon Subtypes and Pro-Inflammatory Cytokines"*,
Principal Investigator: Christine Brostjan, PhD

01/2007 – 08/2007 PhD-student
Medical University of Vienna, Austria
Department of Vascular Biology and Thrombosis Research
"Identification and characterization of atheroprotective genes in porcine vasculature, potentially counteracting xenograft rejection", Principal Investigator: Rainer deMartin, PhD

06/2005-12/2006 Diploma student
Medical University of Vienna, Austria
Department of Surgery
Diploma Thesis: *"Induction of Interferon Regulated Genes in Endothelial Cells: Characterization of a Tumor Derived Stimulus and Endothelial Receptor Interactions",* Principal Investigator: Christine Brostjan, PhD

3. RESEARCH GRANTS

2022 – 2023 City of Vienna Fund for Innovative Interdisciplinary Cancer Research (€80k)
2020 – 2024 Austrian Science Fund (FWF-P33430; Co-Applicant with Emilio Casanova (30 % of €400k)
2020 – 2024 Austrian Science Fund (FWF-P32900; Co-Applicant with Emilio Casanova (30 % of €390k)
2019 – 2020 Fellinger Cancer Foundation (€25k)
2018 – 2019 CCC Research Grant (€50k)
2015 - 2017 Fellinger Cancer Foundation (€25k)
2012 - 2014 Erwin Schroedinger Fellowship (FWF-J3398-B23) (€140k)

4. INTERNATIONAL LECTURES

06/2021 A20 in Lung Tumors: Implications for Immunotherapy (Center for Vascular Biology Research, Beth Israel Deaconess Medical Center & Harvard Medical School, Massachusetts, USA, invited lecture, Host: Dr. Carmelo Nucera)
10/2018 *Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis* (University of Ulm, Germany, invited N27 talk, Host: Dr. Jan Tuckermann)
09/2018 Lung tumors escape immune surveillance by downregulation of A20 (EMBO: Cellular signaling and Cancer Therapy, Cavtat, Croatia)
09/2017 *Partial Loss of A20 exacerbates IFNγ dependent Transplant Arteriosclerosis through De-Regulation of IFNβ.* (Joint Meeting of the Federation of European Physiological Societies, Vienna, Austria)
07/2014 *Partial Loss of A20 Aggravates Transplant Arteriosclerosis through De-Regulation of IFNβ/STAT1 Axis, Thereby Enhancing Pathologic IFNγ signaling.* (World Transplant Congress, San Francisco, United States)

5. AWARDS, PROFESSIONAL ACTIVITIES

AWARDS

04/2018 Poster Prize CCC-TRIO – Translational Research & Immuno-Oncology (€2.5k)
05/2014 Excellence in Surgery Research – Harvard Medical School Research Day
07/2012 Poster Prize – Center for Vascular Biology Research 8th Annual Research Retreat
06/2012 Poster of Distinction – American Transplant Congress 2012
05/2012 Excellence in Surgery Research – Inaugural Harvard Medical School Surgery Research Day 2012
11/2011 Beth Israel Deaconess Medical Center Surgery Research Symposium Award 2011 (Harvard Medical School)

EXPERT OPINION

Reviewer for Cancer Letters; Circulation Research; Clinical and Translational Medicine; FASEB; Cancer Communications;; Scientific Reports, Cancer Medicine, etc.

6. TEACHING

at Medical University of Vienna

since 2016 BL 4 - Funktionssysteme und biologische Regulation - Seminar
since 2021 BL 9 - Krankheit, Manifestation und Wahrnehmung, allgemeine Arzneimitteltherapie – Seminar
since 2015 Journal Clubs and Progress Reports & Supervision of PhD and Master students in our laboratory

at FH Campus Wien – Studiengang Biotechnologisches Qualitätsmanagment

since 2019 Physiologie (Vorlesung)
since 2021 Biopharmakologie (Vorlesung)

7. 10 MOST RELEVANT PUBLICATIONS

1 Caratti, B., Fidan, M., Caratti, G., Breitenecker, K., Engler, M., Kazemitash, N., Traut, R., Wittig, R., Casanova, E., Ahmadian, M. R., Tuckermann, J. P.[*✉], **Moll, H. P.**[*✉] & Cirstea, I. C.[*✉] The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth. ***Science Signaling*** **15**, eabm4452, doi:10.1126/scisignal.abm4452 (2022).

2 Breitenecker, K., Homolya, M., Luca, A. C., Lang, V., Trenk, C., Petroczi, G., Mohrherr, J., Horvath, J., Moritsch, S., Haas, L., Kurnaeva, M., Eferl, R., Stoiber, D., Moriggl, R., Bilban, M., Obenauf, A. C., Ferran, C., Dome, B., Laszlo, V., Győrffy, B., Dezso, K., Moldvay, J., Casanova, E. & **Moll, H. P.**[✉] Down-regulation of A20 promotes immune escape of lung adenocarcinomas. ***Science translational medicine*** **13**, doi:10.1126/scitranslmed.abc3911 (2021).

3 **Moll, H. P.**, Pranz, K., Musteanu, M., Grabner, B., Hruschka, N., Mohrherr, J., Aigner, P., Stiedl, P., Brcic, L., Laszlo, V., Schramek, D., Moriggl, R., Eferl, R., Moldvay, J., Dezso, K., Lopez-Casas, P. P., Stoiber, D., Hidalgo, M., Penninger, J., Sibilia, M., Gyorffy, B., Barbacid, M., Dome, B., Popper, H. & Casanova, E. Afatinib restrains K-RAS-driven lung tumorigenesis. ***Science translational medicine*** **10**, doi:10.1126/scitranslmed.aao2301 (2018).

4 Mohrherr, J., Haber, M., Breitenecker, K., Aigner, P., Moritsch, S., Voronin, V., Eferl, R., Moriggl, R., Stoiber, D., Gyorffy, B., Brcic, L., Laszlo, V., Dome, B., Moldvay, J., Dezso, K., Bilban, M., Popper, H., **Moll, H. P.**[✉] & Casanova, E. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression. ***International journal of cancer*** **145**, 3376-3388, doi:10.1002/ijc.32624 (2019).

5 Zboray, K., Mohrherr, J., Stiedl, P., Pranz, K., Wandruszka, L., Grabner, B., Eferl, R., Moriggl, R., Stoiber, D., Sakamoto, K., Wagner, K. U., Popper, H., Casanova, E. & **Moll, H. P.**[✉] AKT3 drives adenoid cystic carcinoma development in salivary glands. ***Cancer medicine*** **7**, 445-453, doi:10.1002/cam4.1293 (2018).

6 Bousquet Mur, E., Bernardo, S., Papon, L., Mancini, M., Fabbrizio, E., Goussard, M., Ferrer, I., Giry, A., Quantin, X., Pujol, J. L., Calvayrac, O., **Moll, H. P.**, Glasson, Y., Pirot, N., Turtoi, A., Canamero, M., Wong, K. K., Yarden, Y., Casanova, E., Soria, J. C., Colinge, J., Siebel, C. W., Mazieres, J., Favre, G., Paz-Ares, L. & Maraver, A. Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. ***The Journal of clinical investigation*** **130**, 612-624, doi:10.1172/jci126896 (2020).
IF: 14,808, JIF Percentile: 98.67 (Medicine, Research & Experimental)

7 Sdelci, S., Rendeiro, A. F., Rathert, P., You, W., Lin, J. G., Ringler, A., Hofstatter, G., **Moll, H. P.**, Gurtl, B., Farlik, M., Schick, S., Klepsch, F., Oldach, M., Buphamalai, P., Schischlik, F., Majek, P., Parapatics, K., Schmidl, C., Schuster, M., Penz, T., Buckley, D. L., Hudecz, O., Imre, R., Wang, S. Y., Maric, H. M., Kralovics, R., Bennett, K. L., Muller, A. C., Mechtler, K., Menche, J., Bradner, J. E., Winter, G. E., Klavins, K., Casanova, E., Bock, C., Zuber, J. & Kubicek, S. MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. ***Nature genetics*** **51**, 990-998,

8 Grabner, B., Schramek, D., Mueller, K. M., **Moll, H. P.**, Svinka, J., Hoffmann, T., Bauer, E., Blaas, L., Hruschka, N., Zboray, K., Stiedl, P., Nivarthi, H., Bogner, E., Gruber, W., Mohr, T., Zwick, R. H., Kenner, L., Poli, V., Aberger, F., Stoiber, D., Egger, G., Esterbauer, H., Zuber, J., Moriggl, R., Eferl, R., Gyorffy, B., Penninger, J. M., Popper, H. & Casanova, E. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. ***Nature communications*** **6**, 6285, doi:10.1038/ncomms7285 (2015).

9 **Moll, H. P.**✉, Mohrherr, J., Breitenecker, K., Haber, M., Voronin, V. & Casanova, E. Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression. ***Journal of visualized experiments : JoVE***, doi:10.3791/58101 (2019).

10 **Moll, H. P.**, Lee, A., Minussi, D. C., da Silva, C. G., Csizmadia, E., Bhasin, M. & Ferran, C. A20 regulates atherogenic interferon (IFN)-γ signaling in vascular cells by modulating basal IFNβ levels. ***The Journal of biological chemistry*** **289**, 30912-30924, doi:10.1074/jbc.M114.591966 (2014).